Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study

AIM: Immune checkpoint inhibitors (ICIs) have updated the treatment landscape for patients with advanced malignancies, while their clinical prospect was hindered by severe immune-related adverse events (irAEs). The aim of this study was to research the association between gut microbiome diversity an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenhui, Ma, Fang, Sun, Bao, Liu, Yiping, Tang, Haoneng, Luo, Jianquan, Chen, Huiqing, Luo, Zhiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716485/
https://www.ncbi.nlm.nih.gov/pubmed/34975845
http://dx.doi.org/10.3389/fimmu.2021.756872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716485/
https://www.ncbi.nlm.nih.gov/pubmed/34975845
http://dx.doi.org/10.3389/fimmu.2021.756872

Ejemplares similares